

Jacopo Burrello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1381852/publications.pdf>

Version: 2024-02-01

68
papers

3,724
citations

186265

28
h-index

133252

59
g-index

68
all docs

68
docs citations

68
times ranked

3170
citing authors

#	ARTICLE	IF	CITATIONS
1	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature. <i>Translational Research</i> , 2022, , .	5.0	8
2	Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles. <i>Vascular Pharmacology</i> , 2022, 145, 106999.	2.1	11
3	Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. <i>Journal of Personalized Medicine</i> , 2022, 12, 990.	2.5	2
4	De novo DNA methylation induced by circulating extracellular vesicles from acute coronary syndrome patients. <i>Atherosclerosis</i> , 2022, 354, 41-52.	0.8	10
5	International Histopathology Consensus for Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 42-54.	3.6	127
6	Quality of life in primary aldosteronism: A prospective observational study. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13419.	3.4	7
7	Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer. <i>Communications Biology</i> , 2021, 4, 119.	4.4	18
8	A Changing Paradigm in Heart Transplantation: An Integrative Approach for Invasive and Non-Invasive Allograft Rejection Monitoring. <i>Biomolecules</i> , 2021, 11, 201.	4.0	11
9	Profiling Inflammatory Extracellular Vesicles in Plasma and Cerebrospinal Fluid: An Optimized Diagnostic Model for Parkinsonâ€™s Disease. <i>Biomedicines</i> , 2021, 9, 230.	3.2	12
10	Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS-CoV-2 infection. <i>EBioMedicine</i> , 2021, 67, 103369.	6.1	61
11	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. <i>Frontiers in Pharmacology</i> , 2021, 12, 668843.	3.5	0
12	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3655-e3664.	3.6	16
13	Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial Hypertension. <i>Hypertension</i> , 2021, 78, 1595-1604.	2.7	10
14	Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2021, 78, 726-737.	2.7	14
15	Extracellular Vesicle Surface Markers as a Diagnostic Tool in Transient Ischemic Attacks. <i>Stroke</i> , 2021, 52, 3335-3347.	2.0	12
16	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1708-1716.	3.6	16
17	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , 2021, 13, 5831.	3.7	5
18	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. <i>Hypertension Research</i> , 2020, 43, 500-510.	2.7	26

#	ARTICLE	IF	CITATIONS
19	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Annals of Surgery</i> , 2020, 272, 1125-1132.	4.2	66
20	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. <i>Hypertension</i> , 2020, 75, 163-172.	2.7	33
21	Effect of Dietary Sodium Modulation on Pig Adrenal Steroidogenesis and Transcriptome Profiles. <i>Hypertension</i> , 2020, 76, 1769-1777.	2.7	5
22	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. <i>JAMA Network Open</i> , 2020, 3, e2016209.	5.9	53
23	An extracellular vesicle epitope profile is associated with acute myocardial infarction. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9945-9957.	3.6	27
24	Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1136-1148.	0.6	54
25	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4382-e4392.	3.6	20
26	Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	45
27	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3706-e3717.	3.6	47
28	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. <i>Hypertension</i> , 2020, 75, 1025-1033.	2.7	60
29	Inflammatory extracellular vesicles prompt heart dysfunction via TLR4-dependent NF- κ B activation. <i>Theranostics</i> , 2020, 10, 2773-2790.	10.0	39
30	Primary Aldosteronism in the Elderly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2320-e2326.	3.6	12
31	Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. <i>European Journal of Endocrinology</i> , 2020, 183, 657-667.	3.7	8
32	Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 784-792.	2.7	17
33	Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 359-367.	2.7	23
34	Detection of orthostatic hypotension with ambulatory blood pressure monitoring in parkinsonâ€™s disease. <i>Hypertension Research</i> , 2019, 42, 1552-1560.	2.7	15
35	Blood pressure circadian rhythm alterations in alpha-synucleinopathies. <i>Journal of Neurology</i> , 2019, 266, 1141-1152.	3.6	25
36	Comparison of Automated Office Blood Pressure With Office and Out-Of-Office Measurement Techniques. <i>Hypertension</i> , 2019, 73, 481-490.	2.7	57

#	ARTICLE	IF	CITATIONS
37	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 274-282.	2.5	28
38	Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 167-176.	2.2	20
39	Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2535-2543.	2.4	34
40	Pharmacological Treatment of Arterial Hypertension in Children and Adolescents. <i>Hypertension</i> , 2018, 72, 306-313.	2.7	32
41	Liddle Syndrome: Review of the Literature and Description of a New Case. <i>International Journal of Molecular Sciences</i> , 2018, 19, 812.	4.1	69
42	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 650-657.	2.7	51
43	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 641-649.	2.7	94
44	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 689-699.	11.4	595
45	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1811-1820.	2.8	520
46	Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. <i>Hypertension</i> , 2017, 70, 875-881.	2.7	35
47	Familial hyperaldosteronism type III. <i>Journal of Human Hypertension</i> , 2017, 31, 776-781.	2.2	37
48	Is Primary Aldosteronism Still Largely Unrecognized?. <i>Hormone and Metabolic Research</i> , 2017, 49, 908-914.	1.5	50
49	A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression. <i>Journal of the Endocrine Society</i> , 2017, 1, 401-406.	0.2	3
50	Is There a Role for Genomics in the Management of Hypertension?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1131.	4.1	40
51	Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 848.	4.1	40
52	Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 83.	3.7	226
53	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. <i>Journal of Hypertension</i> , 2016, 34, 920-927.	0.5	61
54	Guidelines for primary aldosteronism. <i>Journal of Hypertension</i> , 2016, 34, 2253-2257.	0.5	134

#	ARTICLE	IF	CITATIONS
55	Hyperaldosteronism: How to Discriminate Among Different Disease Forms?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 203-208.	2.2	3
56	Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. Endocrine, 2016, 54, 826-829.	2.3	2
57	Issues in the Diagnosis and Treatment of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 73-82.	2.2	0
58	Ambulatory Blood Pressure Monitoringâ€“Derived Shortâ€“Term Blood Pressure Variability in Primary Aldosteronism. Journal of Clinical Hypertension, 2015, 17, 603-608.	2.0	10
59	Subtype Diagnosis of Primary Aldosteronism: Approach to Different Clinical Scenarios. Hormone and Metabolic Research, 2015, 47, 959-966.	1.5	8
60	KCNJ5 Mutations: Sex, Salt and Selection. Hormone and Metabolic Research, 2015, 47, 953-958.	1.5	18
61	Renin and Aldosterone Measurements in the Management of Arterial Hypertension. Hormone and Metabolic Research, 2015, 47, 418-426.	1.5	24
62	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1262-E1269.	3.6	4
63	Aldosterone Suppression on Contralateral Adrenal During Adrenal Vein Sampling Does Not Predict Blood Pressure Response After Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4158-4166.	3.6	62
64	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	2.7	151
65	Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4826-4833.	3.6	348
66	Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism. Current Hypertension Reviews, 2013, 9, 156-165.	0.9	9
67	Primary Aldosteronism: Who Should be Screened?. Hormone and Metabolic Research, 2012, 44, 163-169.	1.5	28
68	Genomic and Non-genomic Effects of Aldosterone. Current Signal Transduction Therapy, 2012, 7, 132-141.	0.5	16